remoxipride has been researched along with Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahangari, G; Bakhtou, H; Deezagi, A; Olfatbakhsh, A | 1 |
| Ahangari, G; Deezagi, A; Hejazi, SH; Pornour, M | 1 |
2 other study(ies) available for remoxipride and Breast Neoplasms
| Article | Year |
|---|---|
The Expression of Dopamine Receptors Gene and their Potential Role in Targeting Breast Cancer Cells with Selective Agonist and Antagonist Drugs. Could it be the Novel Insight to Therapy?
Topics: Adult; Apoptosis; Breast Neoplasms; Bromocriptine; Cabergoline; Cell Line, Tumor; Cell Proliferation; Dopamine; Dopamine Agonists; Dopamine Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Middle Aged; Neoplasm Staging; Receptors, Dopamine; Receptors, Estrogen; Receptors, Progesterone; Remoxipride | 2019 |
New perspective therapy of breast cancer based on selective dopamine receptor D2 agonist and antagonist effects on MCF-7 cell line.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Bromocriptine; Cell Survival; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Patents as Topic; Proliferating Cell Nuclear Antigen; Receptors, Dopamine D2; Remoxipride | 2015 |